• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

  • Home
  • About Us
    • Mission and History
    • Grace-Marie Turner bio
    • Who was Galen?
  • Activities
    • Core Activities
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Ruling Will Thwart Biosimilar Drug Market

POSTED BY Grace-Marie Turner and Roland (Guy) King | The Wall Street Journal on November 30, 2015.

By , 11/30/15

The Europeanization of U.S. drug pricing that Scott Gottlieb warns about in his op-ed (“The Coming Government Takeover of Drug Pricing,” Nov. 23) already has begun. He warns of “reference pricing,” in which the government lumps together drugs that “bureaucrats feel are similar enough that they can be used in place of one another—even if a newer but also more expensive treatment might offer benefits over older alternatives.” In direct violation of congressional intent, the Centers for Medicare & Medicaid Services finalized a rule Oct. 30 explaining how Medicare will pay for physician-administered biosimilar drugs, which are similar but not identical to the original brand-name biologic drug. It decided it would lump all biosimilars that mimic the same original into the same category, i.e., reference pricing.

However, the physical attributes of the biosimilar drug will never be exactly the same as the original biologic or any other biosimilar drug, and this diversity can potentially impact effectiveness and side effects.

Continue Reading…

 

 

Filed Under: Prescription Drugs

Primary Sidebar

Our Annual Report

Health Care Choices 20/20:

A Vision for the Future

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Policy Consensus Group
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medical Education
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • Sun Sentinel
    • The Daily Signal
    • The Heritage Foundation
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute at Donors. © 2023; · Log in